Biogen has halted its investigation into the efficacy of its humanised monoclonal antibody Tysabri (natalizumab) in the treatment of acute ischemic stroke (AIS) after it failed to meet its primary and secondary endpoints in a Phase 2b trial, demonstrating no improvement over placebo.
Ook interessant voor je
Reageer